Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data

Study Summary

This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.

Interventions

No interventions listed.

Study Locations

Facility	City	State	Country
Novartis	Rueil-Malmaison		France

Official Trial Information

View on ClinicalTrials.gov